BioLife Solutions, Inc. (NASDAQ:BLFS) Given Consensus Rating of “Hold” by Analysts

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) have been given an average rating of “Hold” by the eleven analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eight have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $31.3750.

Several equities research analysts have weighed in on BLFS shares. Jefferies Financial Group cut BioLife Solutions from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $30.00 to $31.00 in a research note on Thursday, July 23rd. Benchmark cut BioLife Solutions from a “buy” rating to a “hold” rating in a report on Monday, August 10th. Stephens restated an “equal weight” rating and set a $31.00 price target (down from $32.00) on shares of BioLife Solutions in a report on Monday, July 27th. HC Wainwright downgraded BioLife Solutions from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $32.00 to $31.00 in a research report on Thursday, July 23rd. Finally, TD Cowen lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $33.00 to $31.00 in a research note on Wednesday, July 22nd.

BioLife Solutions Stock Down 1.3%

BioLife Solutions stock opened at $34.93 on Thursday. The company has a market cap of $1.71 billion, a price-to-earnings ratio of 30.11 and a beta of 1.91. The firm’s fifty day moving average is $32.79 and its 200 day moving average is $26.13. BioLife Solutions has a 52-week low of $17.86 and a 52-week high of $38.10.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.88. The business had revenue of $28.47 million during the quarter, compared to analysts’ expectations of $27.80 million. BioLife Solutions had a net margin of 53.29% and a return on equity of 2.70%. On average, equities research analysts anticipate that BioLife Solutions will post 0.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioLife Solutions

A number of large investors have recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. bought a new stake in BioLife Solutions in the first quarter worth about $283,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of BioLife Solutions by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,422 shares of the medical equipment provider’s stock worth $489,000 after buying an additional 914 shares during the period. Jane Street Group LLC bought a new stake in shares of BioLife Solutions during the 1st quarter worth approximately $1,091,000. Strs Ohio purchased a new position in BioLife Solutions during the 1st quarter valued at $153,000. Finally, Qube Research & Technologies Ltd grew its position in BioLife Solutions by 2,399.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 248,474 shares of the medical equipment provider’s stock valued at $5,352,000 after acquiring an additional 238,533 shares during the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.